DHA supplementation for late onset Stargardt disease: NAT-3 study

BACKGROUND: We analyzed the effects of a docosahexaenoic acid (DHA) supplementation in patients affected with late onset Stargardt disease (STGD). METHODS: DHA (840 mg/day) was given to 20 STGD patients for six months. A complete ophthalmologic examination, including best-corrected visual acuity (BC...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Querques, Giuseppe, Benlian, Pascale, Chanu, Bernard, Leveziel, Nicolas, Coscas, Gabriel, Soubrane, Gisele, Souied, Eric H
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2010
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2909886/
https://ncbi.nlm.nih.gov/pubmed/20668719
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados